Stock LSTA LISATA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Lisata Therapeutics, Inc.

Equities

LSTA

US1280583022

Delayed Nasdaq
Other stock markets
 09:53:58 2024-04-16 am EDT 		5-day change 1st Jan Change
2.84 USD +0.35% Intraday chart for Lisata Therapeutics, Inc. -5.96% +4.03%
Apr. 09 Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma CI
Mar. 21 Sector Update: Health Care Stocks Higher in Late Afternoon Trading MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
GL
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
CI
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events
GL
Sector Update: Health Care Stocks Higher in Late Afternoon Trading
MT
Sector Update: Health Care Stocks Higher in Afternoon Trading
MT
Lisata Therapeutics Says FDA Grants Rare Pediatric Disease Designation to Osteosarcoma Drug
MT
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
GL
Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ
AQ
Transcript : Lisata Therapeutics, Inc., 2023 Earnings Call, Feb 29, 2024
Lisata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
GL
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time
GL
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time
AQ
Lisata Therapeutics to Present at BIO CEO & Investor Conference
GL
Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico
AQ
Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme
GL
Lisata Therapeutics, Inc. Announces First Patient Treated in the Phase 2A Trial of Lsta1 in Patients with Glioblastoma Multiforme
CI
Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy
GL
Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy
AQ
Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LSTA Stock
  4. News Lisata Therapeutics, Inc.